Acacia Research Corporation — Q2 2013 Form 10-Q
Business and period: For the quarter and six months ended June 30, 2013. Acacia’s subsidiaries acquire, develop, license and enforce patent rights; the company reported more than 274 patent portfolios under ownership or control. Results are unaudited.
Financial performance
| Metric | Q2 2013 | Q2 2012 | Six months 2013 | Six months 2012 |
|---|---|---|---|---|
| Revenue | $23.1 million | $50.5 million | $100.0 million | $149.5 million |
| Operating income (loss) | ($22.9) million | $9.8 million | ($15.8) million | $74.1 million |
| Net income (loss) attributable to Acacia | ($12.5) million | $6.3 million | ($7.4) million | $56.2 million |
| Diluted EPS | ($0.26) | $0.13 | ($0.15) | $1.19 |
- Revenue fell 54% in Q2 and 33% in the first half year over year. Management attributed the revenue decline primarily to lower average revenue per agreement: $537,000 versus $1.329 million in Q2 and $1.388 million versus $1.917 million for the six-month periods. Q2 agreements increased to 43 from 38; first-half agreements declined to 72 from 78.
- Operating costs and expenses rose 13% in Q2 and 54% in the first half. Patent litigation and licensing expense was $9.9 million in Q2 and $19.6 million for six months; patent amortization was $12.6 million and $24.3 million, respectively. First-half inventor royalties and contingent legal fees increased 57% combined despite lower revenue.
- Net loss margins were approximately 54% for Q2 and 7% for the first half, compared with net income margins of approximately 13% and 38% in the prior-year periods.
- First-half operating cash flow was $18.1 million, down from $63.4 million. Investing activities used $87.9 million, including net purchases of available-for-sale investments and $6.3 million of patent acquisition costs paid. Financing activities used $3.1 million, including the first $6.1 million quarterly dividend.
- Cash and cash equivalents were $148.9 million and short-term investments were $171.2 million at June 30, totaling $320.1 million, versus $311.3 million at year-end 2012. Working capital was $309.8 million. The company reported no long-term debt or committed credit lines.
Changes, outlook and risks
- Three licensees represented 41%, 20% and 12% of Q2 revenue; three represented 50%, 15% and 11% of first-half revenue. Licensee concentration and quarter-to-quarter revenue variability are material features of the business.
- Acacia acquired or obtained rights to 16 patent portfolios in the first half and invested $10.8 million in Q2 portfolio advances, including $8.5 million accrued for future payments. Patent portfolios under ownership or control increased from 250 at December 31, 2012 to approximately 274 at June 30, 2013.
- Management said cash, investments, expected operating cash flows and other available sources should meet requirements through at least August 2014. The filing gives no specific revenue or earnings guidance. Management expects legal expenses to fluctuate with prosecution, litigation and licensing activity and described growth opportunities in technology, energy, medical technology and international markets.
- The board adopted an expected annual dividend of $0.50 per share, paid quarterly at $0.125 per share; future dividends remain at board discretion. A second quarterly dividend was announced after quarter-end. The share repurchase authorization was extended through August 15, 2013, but no shares were repurchased in the first half.
- Key risks include uncertain licensing recoveries, litigation outcomes and costs, possible material sanctions or fee awards in enforcement cases, changing regulation, and reliance on concentrated licensee revenue. Patent terminations and recoveries of acquisition costs also accelerated amortization expense by $956,000 and $612,000, respectively, in the first half.
- Prior-year earnings included a $10.2 million tax benefit from releasing a deferred-tax valuation allowance; this makes year-over-year earnings comparisons less comparable. The 2013 first-half effective tax rate was approximately 41%, versus 25% in 2012.
Investor verification points
- Review the timing and collectibility of the $16.8 million accounts receivable balance and the concentration of revenue among major licensees.
- Assess whether new licensing programs and patent acquisitions can offset lower average revenue per agreement and rising patent-related costs and amortization.
- Monitor litigation results, legal expense trends, potential sanctions or fee awards, and the conversion of accrued patent acquisition commitments into cash payments.
- Verify the sustainability of operating cash flow, the dividend policy and management’s stated liquidity runway, particularly if licensing receipts remain volatile.